Overview Dividends

(MIRM) Mirum Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6047491013

LIVMARLI, Cholbam, Chenodal, Volixibat

Biotechnology
Market Cap in USD: 3,313m
IPO / Inception: 2019-07-18
Return 12m vs S&P 500: 66.7%

EPS (Earnings per Share)

EPS (Earnings per Share) of MIRM over the last years for every Quarter: "2020-12": -1.43, "2021-03": -1.69, "2021-06": -1.45, "2021-09": -1.55, "2021-12": -1.66, "2022-03": -1.17, "2022-06": -0.84, "2022-09": -1.02, "2022-12": -0.99, "2023-03": -0.8, "2023-06": -1.94, "2023-09": -0.57, "2023-12": -0.66, "2024-03": -0.54, "2024-06": -0.52, "2024-09": -0.2979, "2024-12": -0.49, "2025-03": -0.3, "2025-06": -0.12, "2025-09": 0.05,
EPS CAGR: 61.31%
EPS Trend: 85.3%
Last SUE: 0.91
Qual. Beats: 1

Revenue

Revenue of MIRM over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 11, 2021-09: 5, 2021-12: 3.138, 2022-03: 12.892, 2022-06: 17.484, 2022-09: 18.78, 2022-12: 27.906, 2023-03: 31.598, 2023-06: 37.497, 2023-09: 47.725, 2023-12: 69.554, 2024-03: 69.222, 2024-06: 77.875, 2024-09: 90.377, 2024-12: 99.414, 2025-03: 111.585, 2025-06: 127.785, 2025-09: 133.009999,
Rev. CAGR: 171.60%
Rev. Trend: 83.5%
Last SUE: 0.36
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 55.0%
Value at Risk 5%th 81.3%
Relative Tail Risk -10.01%
Reward TTM
Sharpe Ratio 1.78
Alpha 84.23
CAGR/Max DD 2.07
Character TTM
Hurst Exponent 0.550
Beta 0.782
Beta Downside 0.869
Drawdowns 3y
Max DD 32.52%
Mean DD 10.20%
Median DD 8.52%

Description: MIRM Mirum Pharmaceuticals November 10, 2025

Mirum Pharmaceuticals (NASDAQ:MIRM) is a U.S. biotech that develops and commercializes oral, minimally absorbed therapies targeting rare and orphan diseases, most notably its FDA-approved IBAT inhibitor LIVMARLI for cholestatic pruritus in Alagille syndrome patients.

Beyond LIVMARLI, the firm markets Cholbam (cholic acid) for bile-acid synthesis disorders and Chenodal (chenodiol) for gallbladder radiolucent stones, while advancing Volixibat in a Phase 2b trial for adult cholestatic liver disease and pursuing a Phase 3 study of Chenodal for cerebrotendinous xanthomatosis.

As of its latest Q2 2024 filing, Mirum reported cash and cash equivalents of approximately $85 million, giving it an estimated 12-month runway at current burn rates; its market capitalization hovered around $250 million, reflecting a price-to-sales multiple near 12× for its niche rare-disease portfolio.

Key sector drivers include the U.S. Orphan Drug Act’s 7-year exclusivity and tax credits, which historically boost rare-disease biotech valuations by ~30 % versus non-orphan peers, and a projected CAGR of 11 % for the global orphan-drug market through 2030, driven by increasing diagnostic capabilities and payer willingness to fund high-impact therapies.

For a deeper, data-driven dive into Mirum’s valuation nuances, you may find ValueRay’s analytical tools useful.

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (-41.4m TTM) > 0 and > 6% of Revenue (6% = 28.3m TTM)
FCFTA 0.06 (>2.0%) and ΔFCFTA 9.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 78.47% (prev 88.22%; Δ -9.76pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 44.7m > Net Income -41.4m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 3.31 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (57.0m) change vs 12m ago 19.28% (target <= -2.0% for YES)
Gross Margin 79.92% (prev 72.68%; Δ 7.24pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 64.94% (prev 45.97%; Δ 18.97pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -2.67 (EBITDA TTM -5.49m / Interest Expense TTM 11.1m) >= 6 (WARN >= 3)

Altman Z'' -1.34

(A) 0.47 = (Total Current Assets 530.6m - Total Current Liabilities 160.4m) / Total Assets 785.1m
(B) -0.84 = Retained Earnings (Balance) -661.8m / Total Assets 785.1m
(C) -0.04 = EBIT TTM -29.7m / Avg Total Assets 726.5m
(D) -1.34 = Book Value of Equity -661.8m / Total Liabilities 493.1m
Total Rating: -1.34 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 47.49

1. Piotroski 4.50pt
2. FCF Yield 1.36%
3. FCF Margin 9.39%
4. Debt/Equity 1.09
5. Debt/Ebitda -6.70
6. ROIC - WACC (= -13.96)%
7. RoE -16.47%
8. Rev. Trend 83.52%
9. EPS Trend 85.34%

What is the price of MIRM shares?

As of December 23, 2025, the stock is trading at USD 81.07 with a total of 975,828 shares traded.
Over the past week, the price has changed by +26.47%, over one month by +12.29%, over three months by +9.66% and over the past year by +94.27%.

Is MIRM a buy, sell or hold?

Mirum Pharmaceuticals has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MIRM.
  • Strong Buy: 6
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MIRM price?

Issuer Target Up/Down from current
Wallstreet Target Price 98 20.9%
Analysts Target Price 98 20.9%
ValueRay Target Price 133.5 64.7%

MIRM Fundamental Data Overview December 17, 2025

Market Cap USD = 3.31b (3.31b USD * 1.0 USD.USD)
P/E Forward = 39.6825
P/S = 7.022
P/B = 11.5032
Beta = 0.424
Revenue TTM = 471.8m USD
EBIT TTM = -29.7m USD
EBITDA TTM = -5.49m USD
Long Term Debt = 309.4m USD (from longTermDebt, last quarter)
Short Term Debt = 2.04m USD (from shortTermDebt, last quarter)
Debt = 318.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.26b USD (3.31b + Debt 318.8m - CCE 375.5m)
Interest Coverage Ratio = -2.67 (Ebit TTM -29.7m / Interest Expense TTM 11.1m)
FCF Yield = 1.36% (FCF TTM 44.3m / Enterprise Value 3.26b)
FCF Margin = 9.39% (FCF TTM 44.3m / Revenue TTM 471.8m)
Net Margin = -8.78% (Net Income TTM -41.4m / Revenue TTM 471.8m)
Gross Margin = 79.92% ((Revenue TTM 471.8m - Cost of Revenue TTM 94.8m) / Revenue TTM)
Gross Margin QoQ = 80.80% (prev 81.67%)
Tobins Q-Ratio = 4.15 (Enterprise Value 3.26b / Total Assets 785.1m)
Interest Expense / Debt = 0.11% (Interest Expense 355.0k / Debt 318.8m)
Taxrate = -9.91% (negative due to tax credits) (-262.0k / 2.64m)
NOPAT = -32.7m (EBIT -29.7m * (1 - -9.91%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 3.31 (Total Current Assets 530.6m / Total Current Liabilities 160.4m)
Debt / Equity = 1.09 (Debt 318.8m / totalStockholderEquity, last quarter 292.0m)
Debt / EBITDA = -6.70 (negative EBITDA) (Net Debt 36.7m / EBITDA -5.49m)
Debt / FCF = 0.83 (Net Debt 36.7m / FCF TTM 44.3m)
Total Stockholder Equity = 251.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.28% (Net Income -41.4m / Total Assets 785.1m)
RoE = -16.47% (Net Income TTM -41.4m / Total Stockholder Equity 251.5m)
RoCE = -5.30% (EBIT -29.7m / Capital Employed (Equity 251.5m + L.T.Debt 309.4m))
RoIC = -5.83% (negative operating profit) (NOPAT -32.7m / Invested Capital 560.2m)
WACC = 8.13% (E(3.31b)/V(3.63b) * Re(8.90%) + D(318.8m)/V(3.63b) * Rd(0.11%) * (1-Tc(-0.10)))
Discount Rate = 8.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 10.45%
[DCF Debug] Terminal Value 66.67% ; FCFE base≈44.3m ; Y1≈29.1m ; Y5≈13.3m
Fair Price DCF = 4.40 (DCF Value 227.5m / Shares Outstanding 51.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 85.34 | EPS CAGR: 61.31% | SUE: 0.91 | # QB: 1
Revenue Correlation: 83.52 | Revenue CAGR: 171.6% | SUE: 0.36 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.07 | Chg30d=-0.041 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-0.01 | Chg30d=-0.391 | Revisions Net=-1 | Growth EPS=+96.2% | Growth Revenue=+19.9%

Additional Sources for MIRM Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle